The HRT Index · Perimenopause & Menopause

The Best Online HRT Providers for Women in 2026

We evaluated 7 online HRT providers for women in perimenopause and menopause — Midi, Alloy, Winona, Evernow, Hers, Pandia Health, and Wisp — scoring each on hormones offered, delivery methods, lab requirements, cost, clinician access, state availability, and the practical experience of becoming a patient.

Find your menopause care options →Compare Midi, Alloy, Winona, Evernow

The HRT Index Editorial TeamIndependent women's health research

Published: May 15, 2026Last reviewed: May 25, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you. Our reviews and rankings are independent — see our full disclosure and methodology.

This article is educational and is not medical advice. Consult your clinician before starting, stopping, or changing hormone therapy. Individual responses to HRT vary; the right hormones, doses, and delivery methods for you depend on your medical history and clinical context.

Jump toOur Picks How We Evaluated The Reviews Comparison Table Hormones Explained How to Choose FAQ

Our Picks

The shortlist

Seven award designations, applied to the providers below in this evaluation cycle. Each award reflects editorial judgement against our published criteria. Read the full review on each provider below.

BEST OVERALL
Midi Health
The only provider in our cohort that combines menopause-specialty clinicians with direct billing of major commercial insurance plans for the clinical encounter. Read review ↓
BEST FOR COMPREHENSIVE CARE
Alloy
Coordinates HRT alongside adjacent perimenopause concerns (sleep, libido, hair, skin, vaginal symptoms) under one clinician relationship. Read review ↓
BEST FOR BIOIDENTICAL HRT
Winona
The deepest bioidentical formulary in our cohort, including compounded estradiol and progesterone preparations where clinically appropriate. Read review ↓
BEST FOR PERIMENOPAUSE
Evernow
The clearest perimenopause-specific intake in our cohort, with cyclic progesterone protocols where appropriate and an understanding that perimenopausal labs are often non-diagnostic. Read review ↓
BEST FOR LOW-EFFORT START
Hers
The shortest path from intake to first prescription, with the most predictable bundled pricing in our cohort. Read review ↓
BEST FOR CONTINUITY
Pandia Health
Strongest emphasis in the cohort on uninterrupted medication delivery and a sustained clinician relationship across the perimenopause-to-postmenopause arc. Read review ↓
BEST BUDGET
Wisp
Lowest-cost route in our cohort to a legitimate vaginal-estrogen prescription for a defined symptom set. Read review ↓

The Report

The United States is currently home to roughly 50 million women in some stage of perimenopause or menopause. Most of them are symptomatic, statistically. Many of them do not know it. The perimenopausal arc — the years before the final menstrual period, during which estrogen and progesterone production becomes erratic and then declines — frequently begins in the late thirties or early forties, runs for four to ten years, and produces a constellation of symptoms most women are not taught to connect to a hormonal shift: sleep that quietly falls apart, mood that flattens or sharpens, cognitive friction at work, joint pain that arrives without warning, periods that lengthen or vanish or both.

The clinical infrastructure designed to help her is, in most cases, not equipped to. Most US medical schools dedicate fewer than two hours of instruction to menopause in four years of medical education. Survey work by the Menopause Society and others has consistently found that the majority of practicing OB/GYNs describe themselves as “not adequately trained” in menopause management. Family-medicine and internal-medicine training is, on average, even thinner on the subject. The result is that a woman in her mid-forties who walks into her primary-care appointment describing exhaustion, mood changes, and disrupted sleep is statistically likely to leave with a prescription for an SSRI, a sleep aid, or a stress talk — and considerably less likely to leave with a conversation about hormone therapy.

The shadow over the conversation is the 2002 Women's Health Initiative (WHI) study, whose initial press release cast HRT in the worst possible light and caused a generation of clinicians to stop prescribing it. The data has since been substantially re-evaluated. For women initiating HRT within ten years of menopause onset, the risk-benefit picture is meaningfully different from what the WHI's 2002 framing suggested. The Menopause Society, the British Menopause Society, and the major international guidelines bodies have revised their positions accordingly over the past decade. The training gap, however, has not closed at the same rate, which is why a corrected understanding has been slow to reach the patient sitting in the exam room.

Online HRT — the cluster of telehealth practices that have emerged in the past several years to prescribe estradiol, progesterone, and in some cases testosterone directly to women through video visits — exists in the space where that conversation is not happening in person. The category is uneven. Some practices are run by menopause-trained clinicians and operate to a standard that would be the envy of most primary care. Some are not. The point of this report is to tell you, honestly, which is which.

The contemporary consensus is well summarized in two documents the rest of this report leans on. The Menopause Society's 2022 hormone therapy position statement remains the standing U.S. clinical synthesis: hormone therapy is the most effective treatment available for vasomotor symptoms and for the genitourinary syndrome of menopause, with risks that vary by type, dose, duration, route, timing, and whether a progestogen is included. The U.S. Food and Drug Administration updated the boxed-warning labelling on systemic menopausal hormone therapy products in February 2026, removing several of the broad cardiovascular and breast-cancer statements that had been on the labels since 2003 and bringing the regulatory communication closer to the position the menopause societies had already held for years. The endometrial-cancer warning for unopposed systemic estrogen in women with a uterus was retained — which is the clinical reason a progestogen is still required for this population. The benefits-and-risks frame we use across this site is the one those documents support; we cover it in detail on HRT benefits and risks.

This report is written for the woman who has been dismissed, told to “just push through it,” or handed an SSRI when she wanted to discuss hormones. It is independent — see our affiliate disclosure and methodology. It is editorial research, not medical advice; nothing here is a substitute for a real conversation with a clinician who knows you.

Methodology

How we evaluated online HRT providers for women.

We held every provider against a seven-criterion framework. None of the criteria are unique to The HRT Index; they are the questions any careful clinician or any well-organised patient would ask. We weighted them against the realities of how women actually use online HRT — what matters when the symptoms arrive at 11pm on a Tuesday, what matters six months in, and what matters when something goes wrong.

1. Hormones offered and delivery methods

Estradiol delivered as a transdermal patch, a transdermal gel, an oral tablet, or a topical cream; micronized progesterone (oral or vaginal); testosterone where the practice prescribes it; combined therapy options. We distinguished between FDA-approved bioidentical products and compounded preparations, and we noted which practices offer which.

2. Clinical model

Whether the practice is MD/NP/PA-led, the degree of menopause-specific training (NCMP credentials, residency focus, continuing education), and the structure of the patient-clinician relationship: one-and-done prescribing versus ongoing care with messaging access between visits.

3. Lab and monitoring requirements

Whether baseline labs are required, encouraged, or optional; symptom-based prescribing versus lab-driven workups; at-home test kits versus external lab orders; follow-up monitoring cadence and what gets tracked.

4. Pricing transparency and unit economics

Consultation cost, medication cost, total predictable monthly outlay, subscription model versus à la carte, the existence of bundled pricing, and whether the practice bills commercial insurance for the clinical encounter.

5. State availability

State licensing matters more than category buyers tend to realise; some practices serve fifty states, some serve fewer than twenty. We noted the working coverage at the time of evaluation and the rough trajectory of expansion.

6. Practice management and user experience

How the intake flow feels, how prescriptions are delivered (mail pharmacy versus local retail), how follow-up appointments are scheduled, how refills work, and how questions are handled between visits.

7. Cancellation and continuation policies

Lock-in clauses, refund policies, prescription portability if a patient decides to move providers. The category has a few cautionary tales here; we flag them where they apply.

Full methodology, including our scoring rubric, medical review policy, and conflict-of-interest disclosures, is on the methodology page →.

The Context

Why online HRT is having a moment now — and why women have been left behind.

The post-WHI reckoning is the operational story underneath the cultural one. In 2002, the Women's Health Initiative published the first interim results of its combined estrogen-plus-progestin arm, and the press release that accompanied them was unusually alarming. The cardiovascular and breast-cancer signals were communicated as relative risks rather than absolute risks, the study population (average age 63, well past the typical menopausal transition) was not distinguished from the population most patients then on HRT actually belonged to, and the transdermal-versus-oral distinction did not appear at the top of the communication at all. HRT prescribing fell sharply within months.

The slower story is the re-analysis. By 2017 the Menopause Society had issued a revised position statement clarifying that for women under 60 or within ten years of menopause onset, the benefit-risk balance for HRT is generally favourable for those with bothersome menopausal symptoms. The 2022 update was more pointed: HRT remains the most effective treatment for vasomotor symptoms and is also effective for prevention of bone loss in appropriate candidates. The 2024 update has continued in that direction. The International Menopause Society, the British Menopause Society, the European Menopause and Andropause Society, and the major obstetrics-and-gynecology bodies have largely converged.

Inside that converged picture sits a credential most patients have never heard of: the NCMP, or Certified Menopause Practitioner. The Menopause Society (previously the North American Menopause Society) administers the credential to clinicians who have demonstrated focused expertise in menopause management. The number of NCMP-credentialed clinicians per US state is small in absolute terms — most counties have none — and the bulk of online HRT's value proposition is that it connects patients to the small population of menopause-focused clinicians regardless of where the patient lives.

The in-person OB/GYN visit is, for most women seeking HRT, the wrong starting point. The visit is short. The training base is thin. The defensive instinct — instilled by years of post-WHI litigation avoidance — is to decline rather than prescribe. The pattern repeats: the patient brings hormones up, the clinician deflects, the conversation ends. None of this is the individual clinician's fault; the structural setting was not built to support the conversation. Online HRT exists in part because the structural setting has not been fixed.

The patient-side cultural shift has been faster than the clinical one. Naomi Watts, Halle Berry, Drew Barrymore, Tamsen Fadal, Mary Claire Haver, Lisa Mosconi, Jen Gunter, Heather Hirsch, Avrum Bluming and other writers, broadcasters, and clinicians have moved menopause out of the back pages of women's health and into the front pages of mainstream media. The reading public for this topic is large, motivated, and increasingly well-informed. The reading public is, in many cases, ahead of its own clinicians, which is its own statement of how the gap looks from the patient side.

The online HRT category needs to be evaluated against that backdrop. A telehealth practice that does no more than mail patients an SSRI and an estrogen patch without a real clinical encounter is not the answer; a menopause-specialist practice that meets patients with a real history, meaningful prescribing, and ongoing access is. The point of the reviews below is to separate the two.

If you have been told “you're too young for menopause,” “this is just stress,” or “your labs look normal” — you are not alone, and you are not necessarily wrong about your own body.

The Reviews

The 7 providers, reviewed.

The reviews below are written in editorial voice rather than as feature checklists. Each review opens with a depth-of-evaluation note, in keeping with our policy of never claiming evaluation we did not perform. Affiliate links are labelled. Where awards are given, the rationale is attached.

BEST OVERALL

Midi Health

A menopause-focused telehealth practice that bills most major commercial insurance plans for the clinical visit.

How we evaluated this provider: Documentation review. Documentation review of public clinical materials, payer network disclosures, and patient-facing pricing. Hands-on consult scheduled for the next refresh cycle.

Midi Health is the most legible 'insurance plus menopause specialty' option in the cohort. Most women's-midlife telehealth services in this category do not bill commercial insurance for the clinical encounter; Midi is the conspicuous exception, and for an insured patient that single fact often dominates the decision. The practice is in-network with a meaningful share of major commercial plans (Aetna, Blue Cross plans, UnitedHealthcare, Cigna in many markets), and patients owe a standard copay rather than the cash visit fee that defines the rest of the category.

The clinical model is built around clinicians with menopause-specific training, and the vendor's public materials cite a roster that includes several clinicians holding the NCMP (Certified Menopause Practitioner) credential from The Menopause Society. The formulary is FDA-approved bioidentical hormones — transdermal estradiol patches, oral estradiol, vaginal estradiol — paired with oral or vaginal micronized progesterone for patients with a uterus. Low-dose testosterone is prescribed in defined clinical contexts; off-label compounded preparations are not part of the standard offering.

The honest framing: insurance changes the price and it changes the cadence. Patients should expect shorter individual visits than at the higher-priced membership-model practices, and coverage detail is plan-specific. If the first priority is paying less while still seeing a clinician who actually knows this material, Midi is the natural starting point.

What we like

Direct insurance billing for clinical visits (rare in this category)
Menopause-trained clinical leadership; NCMP credentials on staff
All 50 states; broad formulary including vaginal estrogen and testosterone where clinically indicated
Ongoing clinician messaging between visits

Trade-offs

Insurance copays and coverage vary by plan
Insurance-driven model can mean shorter individual visits
Compounded preparations are not part of the standard offering

Hormones: FDA-approved estradiol (patch, oral, vaginal), micronized progesterone (oral, vaginal), low-dose testosterone where clinically appropriate
Delivery: Patches · Pills · Vaginal · Creams
Clinical model: NPs and MDs with menopause-specific training; several NCMP-credentialed clinicians on staff per vendor materials
Labs: Symptom-first prescribing; labs ordered when clinically indicated and typically run through insurance
Availability: Available in all 50 U.S. states (verify on vendor site)
Pricing: Insurance / $

Best for: An insured woman who wants menopause-specialist care without paying full out-of-pocket for the clinical visits.

Visit Midi HealthSponsored link · we may earn a commission

BEST FOR COMPREHENSIVE CARE

Alloy

A menopause-and-midlife-women's-health practice with a broad hormone formulary and an ongoing clinician relationship.

How we evaluated this provider: Documentation review. Documentation review of the vendor's clinical materials, prescribing notes, and patient-facing pricing. Patient-experience interviews are pending.

Alloy is built around the premise that midlife women's-health complaints rarely arrive alone, and that a single clinical team coordinating across them produces better care than a stack of single-condition prescribers. The membership model — an annual subscription that unlocks ongoing clinician messaging — sits behind a roster that includes menopause-specialty physicians on the medical advisory team. The practice's public materials emphasize NCMP-credentialed clinical leadership and a prescribing posture that uses FDA-approved bioidentical hormones as the default.

The formulary covers transdermal estradiol patches, oral estradiol, and oral or vaginal micronized progesterone, with vaginal estradiol available for the patient whose symptoms are primarily genitourinary. Adjacent prescriptions — non-hormonal options for sleep, libido, hair, and skin — are part of the same membership, which is the practical reason Alloy earns the comprehensive-care framing. Compounded bioidenticals and off-label male-dose testosterone are not part of the standard offering; patients seeking those specifically should look elsewhere.

The trade-off is the trade-off of the membership category: the clinical visit is out-of-pocket, and the all-in monthly cost adds the subscription, the medication, and any labs the clinician orders. For an uninsured or under-insured patient whose first priority is paying less, Midi will typically be the better economic fit. For a patient who already pays for primary care out-of-pocket and wants one clinical team for the midlife transition, Alloy's scope is the strongest argument.

What we like

Menopause-specialty clinical leadership
Broad scope: HRT plus adjacent women's-midlife Rx (vaginal symptoms, libido, sleep, hair, skin)
Membership unlocks ongoing clinician messaging, not single-encounter prescribing
All 50 states

Trade-offs

Does not bill commercial insurance directly for the clinical visit
Medications stack on top of subscription cost
Compounded preparations are not part of the standard offering

Hormones: Estradiol (patch, oral, vaginal), micronized progesterone (oral, vaginal), testosterone in limited circumstances, plus non-hormonal Rx for adjacent symptoms
Delivery: Patches · Pills · Creams · Vaginal · Adjacent Rx
Clinical model: Menopause-specialty physicians with stated NCMP credentials on the medical advisory team; ongoing clinician relationship
Labs: Symptom-first; labs ordered when clinically indicated; no lab requirement to begin standard HRT
Availability: Available in all 50 U.S. states
Pricing: $$

Best for: A woman in perimenopause or menopause whose symptom set extends beyond hot flashes — sleep, libido, hair, skin, vaginal symptoms — and who wants one clinical team coordinating across all of it.

Visit AlloySponsored link · we may earn a commission

BEST FOR BIOIDENTICAL HRT

Winona

A bioidentical-focused online HRT practice emphasizing transdermal and compounded options with a fast intake flow.

How we evaluated this provider: Documentation review. Documentation review of vendor formulary, compounding-pharmacy partnerships, and prescribing protocols. Patient interviews pending.

Winona occupies the bioidentical-HRT corner of the women's-midlife telehealth market, and earning that framing honestly requires defining the term first. 'Bioidentical' properly refers to hormones structurally identical to those the body produces — 17-beta-estradiol and micronized progesterone are the canonical examples, and both are available in FDA-approved products. 'Compounded bioidentical' refers to preparations mixed by a compounding pharmacy to a clinician's specification. The two are frequently conflated in marketing copy across the category; they are not the same thing.

Winona's default is bioidentical formulations — transdermal patches, creams, gels, and oral micronized progesterone — with compounded options available where a patient's clinical picture makes a standard product unsuitable. The intake flow is unusually short for the depth of formulary on offer, and the practice does not require baseline labs before starting standard prescribing. The medication ships through a partner compounding pharmacy.

The patient who gets the most value out of Winona has already done her reading, has decided she wants a bioidentical/transdermal approach specifically, and understands the FDA-approved-versus-compounded distinction well enough to make an informed choice with her clinician. For the patient who simply wants the lowest-effort path to a legitimate HRT prescription, Hers will be a closer fit. For the patient who wants insurance to pay for the visit, Midi will be the natural starting point.

What we like

Deepest bioidentical and compounded formulary in the cohort
Fast intake-to-prescription window
Transdermal-first prescribing posture (patches, creams, gels)
No lab requirement to begin standard prescribing

Trade-offs

Does not bill commercial insurance
Compounded preparations are not FDA-approved as combination products; the distinction matters and is worth understanding
Less depth of ongoing clinician relationship than membership-model practices

Hormones: Bioidentical estradiol (patch, cream, gel, troche), micronized progesterone (oral, vaginal, troche), compounded preparations where clinically appropriate
Delivery: Patches · Creams · Gels · Troches · Compounded
Clinical model: MDs and NPs with a stated bioidentical-HRT focus; intake-driven prescribing with optional ongoing messaging
Labs: Symptom-first; optional lab add-on available; no lab requirement to begin standard prescribing
Availability: Available in most U.S. states (verify on vendor site)
Pricing: $$

Best for: A woman who has decided she wants bioidentical, primarily transdermal preparations and who values a fast, low-friction path from intake to first prescription.

Visit WinonaSponsored link · we may earn a commission

BEST FOR PERIMENOPAUSE

Evernow

A perimenopause-and-menopause practice calibrated for the transition rather than only the postmenopausal endpoint, with strong messaging-based clinician support.

How we evaluated this provider: Documentation review. Documentation review of the vendor's clinical materials, intake flow, and prescribing notes.

Perimenopause is the transition itself — the years (often four to ten) before the final menstrual period, during which estrogen and progesterone production becomes erratic before declining. The standard clinical mistake, both in primary care and across a non-trivial number of telehealth platforms, is to treat a perimenopausal patient as though she were already postmenopausal: to look for sustained low estradiol on a single blood draw, fail to find it, and conclude she is not a candidate for hormone therapy. Evernow's intake and prescribing posture push against that mistake directly.

The clinical model is asynchronous and messaging-based, which is the most consequential operational fact about the service. There is no scheduled video visit; the patient completes a detailed intake, the clinician reviews and responds in writing, and the ongoing relationship runs through secure messaging. The formulary covers FDA-approved estradiol (patch, oral) with both cyclic and continuous micronized progesterone — a meaningful detail, because a still-cycling perimenopausal patient may benefit from cyclic progesterone that complements rather than overrides her endogenous cycle. Non-hormonal options (paroxetine, gabapentin) are part of the offering for patients who cannot or do not want to take HRT.

The honest limitation: asynchronous care suits some patients and frustrates others. A patient who specifically wants a scheduled video conversation with her prescribing clinician should look elsewhere. A patient who values the ability to write a careful question at 11pm and get a written, considered answer the next day will find this model unusually well-suited to perimenopause specifically.

What we like

Perimenopause-calibrated intake rather than treating perimenopause as early postmenopause
Cyclic progesterone protocols where appropriate
Non-hormonal Rx (paroxetine, gabapentin) available for patients who cannot or do not want to take HRT
Bundled subscription includes standard medications

Trade-offs

Asynchronous messaging-based care; not a video-visit model
Does not bill commercial insurance
Lower-dose starting protocols mean a longer titration runway in some patients

Hormones: Estradiol (patch, oral), cyclic and continuous micronized progesterone, plus non-hormonal Rx (paroxetine, gabapentin) where indicated
Delivery: Patches · Pills · Cyclic protocols · Non-hormonal Rx
Clinical model: Menopause-trained clinicians with stated perimenopause focus; asynchronous messaging-based care model
Labs: Symptom-first; intake recognizes that perimenopausal labs often fluctuate and may not be diagnostic
Availability: Available in all 50 U.S. states
Pricing: $$

Best for: A woman in her late 30s or 40s with irregular cycles, sleep changes, mood shifts, or other early perimenopausal signals — particularly one who has been told by another clinician that her labs are 'normal.'

Visit EvernowSponsored link · we may earn a commission

BEST FOR LOW-EFFORT START

Hers

A consumer-facing women's-health platform with an entry-level HRT offering and the simplest pricing in the cohort.

How we evaluated this provider: Documentation review. Documentation review of the patient-facing intake flow, pricing, and standard prescribing protocol.

Hers is the most consumer-product-shaped option in the women's-HRT category. Sign-up is short, the intake questionnaire is calibrated to the standard menopausal indications for HRT, and the pricing model is a single bundled monthly fee that includes the clinical encounter and the medication. For a woman who has already made the internal decision to try HRT and wants the lowest-friction path to a legitimate prescription, Hers is the shortest line between the two points.

The formulary is intentionally narrow. Patients can be prescribed oral or transdermal estradiol with oral micronized progesterone added for those with a uterus, and a low-dose vaginal estrogen cream is available for the patient whose symptoms are primarily genitourinary. Compounded preparations, vaginal estrogen rings, and testosterone are not on offer in this evaluation cycle. There is no lab requirement to start standard prescribing.

The honest framing: Hers is a good fit for the patient who knows what she wants and who values predictable cost and fast turnaround. It is not the right starting point for a patient with a complex medical history, for a patient interested in testosterone or compounded preparations, or for a patient who specifically wants an NCMP-credentialed menopause specialist managing her care. For those patients, Alloy, Midi, or Winona will fit better.

What we like

Lowest entry price in the cohort
Fastest intake-to-prescription window in the cohort
Bundled pricing is easy to predict month-to-month
Broad state availability

Trade-offs

Narrower formulary — no compounded or testosterone options
Less depth of clinician relationship than membership or specialist practices
Less menopause-specialty depth; this is a broad women's-health platform first

Hormones: FDA-approved estradiol (oral, patch, vaginal cream), micronized progesterone (oral)
Delivery: Pills · Patches · Vaginal cream
Clinical model: NPs and PAs with women's-health training; consumer-app intake and follow-up
Labs: Symptom-first; no labs required for standard prescribing
Availability: Available in most U.S. states (verify on vendor site)
Pricing: $

Best for: A woman who is reasonably confident she wants to start standard-formulation HRT and is looking for the lowest-friction way to get a legitimate prescription.

Visit HersSponsored link · we may earn a commission

BEST FOR CONTINUITY

Pandia Health

A physician-founded women's-health telehealth practice with a stated focus on serving women of color and on continuity of medication delivery.

How we evaluated this provider: Documentation review. Documentation review of the vendor's clinical materials, founder background, and patient-facing operations.

Pandia Health is the practice in this cohort most clearly built around a continuity argument: the medication is shipped automatically, the clinical relationship persists across visits, and the operating model is designed to keep a patient on therapy rather than to maximize the funnel from intake to first prescription. The founder background is women's-health physician leadership, and the practice has been visible since its early years on the question of who is not getting menopause care — Black women, women in lower-resource counties, women who have been historically dismissed by the primary-care system.

Clinically, the formulary is FDA-approved estradiol (patch, oral, vaginal) paired with oral or vaginal micronized progesterone for patients with a uterus. The practice is intentionally conservative on off-label prescribing and on compounded preparations. Labs are ordered when clinically indicated; there is no lab requirement to begin standard prescribing.

The honest framing: Pandia is the strongest fit for the patient whose first priority is reliability — knowing the medication will arrive, knowing the clinician will be available, knowing the care will not be interrupted by an operational issue she has to chase down. It is not the practice with the deepest bioidentical formulary (Winona) or the lowest entry price (Hers) or the strongest insurance story (Midi). It is the practice most clearly built to stay with a patient over years.

What we like

Physician-founded with stated continuity-of-care focus
Automatic medication shipment reduces the risk of an interruption mid-treatment
Explicit attention to serving women of color, who are historically under-treated in menopause care

Trade-offs

Insurance acceptance is plan- and state-dependent
Narrower formulary than the bioidentical-focused practices
Less menopause-specialty marketing emphasis than Midi or Alloy

Hormones: FDA-approved estradiol (patch, oral, vaginal), micronized progesterone (oral, vaginal)
Delivery: Patches · Pills · Vaginal
Clinical model: Physician-founded; women's-health MDs and NPs; sustained care model with automatic medication shipment
Labs: Symptom-first; labs ordered when clinically indicated
Availability: Available in most U.S. states (verify on vendor site)
Pricing: $$

Best for: A woman who values continuity of care and reliable medication delivery, and who wants a women's-health practice with explicit attention to under-served patient populations.

Visit Pandia HealthSponsored link · we may earn a commission

BEST BUDGET

Wisp

A women's-sexual-health telehealth practice with an entry-priced vaginal-estrogen pathway for genitourinary symptoms of menopause.

How we evaluated this provider: Documentation review. Documentation review of the vendor's narrow-scope prescribing model, pricing, and pharmacy fulfilment.

Genitourinary syndrome of menopause (GSM) is one of the most under-treated conditions in women's health. It is the cluster of vaginal, vulvar, and urinary changes that follow declining estradiol — vaginal dryness, dyspareunia, recurrent urinary tract infections, urinary urgency — and it is treatable, in most patients, with extremely low-dose vaginal estrogen that does not produce meaningful systemic absorption. Many women never connect the symptoms to menopause; many of those who do are told by a primary-care clinician that they need to live with it. They do not.

Wisp's model is narrow on purpose. The practice is calibrated for the GSM patient specifically — the patient who needs a vaginal-estrogen prescription, who does not currently want systemic HRT, and who is being asked to pay as little as possible for a treatment whose generic formulations are inexpensive. The consult is short, the price is low, and the medication is dispensed through standard retail or partner-pharmacy channels.

The trade-off is the trade-off of any narrow-scope service. Wisp will not be the right home for a patient whose symptoms are predominantly systemic (vasomotor, sleep, mood), nor for a patient who wants an ongoing menopause-specialist relationship. As an inexpensive on-ramp for one specific clinical situation, it is the strongest economic option in the cohort.

What we like

Lowest-cost path in the cohort to a legitimate vaginal-estrogen prescription
Narrow scope means a fast, focused intake
No labs required for standard prescribing

Trade-offs

Does not address systemic menopausal symptoms (vasomotor, sleep, mood) at the same depth as the full-HRT practices
Patients who later want full systemic HRT may need to move providers
Less clinician continuity than membership-model practices

Hormones: Low-dose vaginal estradiol (cream, tablet); some systemic options have been introduced and should be confirmed on the vendor site
Delivery: Vaginal cream · Vaginal tablet
Clinical model: NPs and PAs; narrow-scope, single-indication clinical model focused on women's sexual and reproductive health
Labs: Symptom-first; no labs required for standard prescribing
Availability: Available in most U.S. states
Pricing: $

Best for: A woman whose primary symptom burden is vaginal dryness, painful intercourse, or recurrent UTI in the context of menopause — and who does not currently want full systemic HRT.

Visit WispSponsored link · we may earn a commission

At a glance

Comparison table — all 7 providers, side by side.

Click a header to sort. On narrow screens, the table scrolls horizontally and the provider column stays pinned.

	Award	Hormones	Delivery			Best for
Alloy	BEST FOR COMPREHENSIVE CARE	Estradiol (patch, oral, vaginal), micronized progesterone (oral, vaginal), testosterone in limited circumstances, plus non-hormonal Rx for adjacent symptoms	Patches · Pills · Creams · Vaginal · Adjacent Rx	Available in all 50 U.S. states	$$	A woman in perimenopause or menopause whose symptom set extends beyond hot flashes — sleep, libido, hair, skin, vaginal symptoms — and who wants one clinical team coordinating across all of it.
Evernow	BEST FOR PERIMENOPAUSE	Estradiol (patch, oral), cyclic and continuous micronized progesterone, plus non-hormonal Rx (paroxetine, gabapentin) where indicated	Patches · Pills · Cyclic protocols · Non-hormonal Rx	Available in all 50 U.S. states	$$	A woman in her late 30s or 40s with irregular cycles, sleep changes, mood shifts, or other early perimenopausal signals — particularly one who has been told by another clinician that her labs are 'normal.'
Hers	BEST FOR LOW-EFFORT START	FDA-approved estradiol (oral, patch, vaginal cream), micronized progesterone (oral)	Pills · Patches · Vaginal cream	Available in most U.S. states (verify on vendor site)	$	A woman who is reasonably confident she wants to start standard-formulation HRT and is looking for the lowest-friction way to get a legitimate prescription.
Midi Health	BEST OVERALL	FDA-approved estradiol (patch, oral, vaginal), micronized progesterone (oral, vaginal), low-dose testosterone where clinically appropriate	Patches · Pills · Vaginal · Creams	Available in all 50 U.S. states (verify on vendor site)	Insurance / $	An insured woman who wants menopause-specialist care without paying full out-of-pocket for the clinical visits.
Pandia Health	BEST FOR CONTINUITY	FDA-approved estradiol (patch, oral, vaginal), micronized progesterone (oral, vaginal)	Patches · Pills · Vaginal	Available in most U.S. states (verify on vendor site)	$$	A woman who values continuity of care and reliable medication delivery, and who wants a women's-health practice with explicit attention to under-served patient populations.
Winona	BEST FOR BIOIDENTICAL HRT	Bioidentical estradiol (patch, cream, gel, troche), micronized progesterone (oral, vaginal, troche), compounded preparations where clinically appropriate	Patches · Creams · Gels · Troches · Compounded	Available in most U.S. states (verify on vendor site)	$$	A woman who has decided she wants bioidentical, primarily transdermal preparations and who values a fast, low-friction path from intake to first prescription.
Wisp	BEST BUDGET	Low-dose vaginal estradiol (cream, tablet); some systemic options have been introduced and should be confirmed on the vendor site	Vaginal cream · Vaginal tablet	Available in most U.S. states	$	A woman whose primary symptom burden is vaginal dryness, painful intercourse, or recurrent UTI in the context of menopause — and who does not currently want full systemic HRT.

The Context

Hormones, explained.

The conversation about HRT is more legible when the underlying hormones are not treated as interchangeable. The four most common subjects of the conversation are estradiol, progesterone, testosterone, and DHEA. They are not the same molecule and they are not prescribed for the same reasons.

Estradiol

Estradiol — specifically 17-beta-estradiol — is the primary estrogen the ovaries produce during the reproductive years. Production declines across perimenopause and falls sharply after the final menstrual period. Most menopausal symptoms — vasomotor (hot flashes, night sweats), genitourinary (dryness, painful intercourse, urinary changes), and substantial pieces of the mood, cognition, and sleep-architecture picture — track to estradiol decline. Replacement-dose estradiol is the cornerstone of HRT.

Delivery method materially changes the risk profile. Transdermal estradiol (patch, gel, spray, cream) avoids the hepatic first-pass effect, which means it does not raise clotting-factor synthesis the way oral estradiol does. For most patients with any cardiovascular, thrombotic, or metabolic risk in the chart, transdermal is the safer default. Oral estradiol remains a reasonable option for low-risk patients and is sometimes preferable on cost and patient preference grounds.

Progesterone

For a patient with a uterus, estrogen prescribed alone produces endometrial proliferation and an increased risk of endometrial cancer over time. Progesterone — almost always given as oral micronized progesterone in current US practice, sometimes as vaginal — is added to oppose that effect. Micronized progesterone is structurally identical to the body's own progesterone and has a different safety profile from the older synthetic progestins (medroxyprogesterone acetate, norethindrone) that were used in the WHI trial. Oral micronized progesterone also has a mild sedating effect, which is why it is most often dosed at bedtime and is sometimes a useful side benefit for patients with disrupted sleep.

Testosterone

Women produce testosterone, and women experience declining testosterone across midlife. Female testosterone replacement remains, in the US, off-label — there is no FDA-approved testosterone product for women. Where prescribed, testosterone is most commonly indicated for hypoactive sexual desire disorder that persists after adequate estrogen therapy. It is not the right first-line answer for energy, mood, or weight in isolation; clinicians who prescribe it to every female patient as a default are not following current International Menopause Society or Menopause Society guidance.

DHEA

Dehydroepiandrosterone (DHEA) is an adrenal hormone that the body converts into other sex hormones. In the menopause context, vaginal DHEA (prasterone) is an FDA-approved treatment for genitourinary syndrome of menopause and is a useful alternative to vaginal estrogen for some patients. Oral DHEA supplementation, by contrast, is available over the counter, is not well standardised, and is not part of mainstream HRT prescribing.

Decision framework

How to choose the right online HRT provider for you.

No single provider is the best provider for every patient. The decision is a function of where in the perimenopause-to-postmenopause arc you are, what symptoms are driving the conversation, how strongly you want a particular delivery method or hormone, what you can afford, and what kind of clinical relationship you want. Six questions worth answering for yourself before you sign up for anything.

1. Where are you in the transition?

If you are still cycling, even irregularly, you are in perimenopause and a provider with explicit perimenopause-specific intake will serve you better than one that treats every patient as postmenopausal. If your final period is several years behind you, the calculus flips.

2. What is the primary symptom?

Predominantly genitourinary symptoms (dryness, painful intercourse, recurrent UTI) are often well-served by a narrow-scope vaginal estrogen prescription before considering systemic HRT. Predominantly vasomotor symptoms (hot flashes, night sweats) respond best to systemic estradiol. A mixed picture argues for a broader practice.

3. Do you have insurance you want to use?

Most providers in the category do not bill commercial insurance for the visit. If using insurance matters, your shortlist narrows substantially.

4. How much clinician relationship do you want?

A bundled-low-cost service is a different product from a membership practice with messaging access between visits. Both are valid; they are not the same purchase.

5. Do you have contraindications or complex history?

History of hormone-sensitive cancer, history of venous thromboembolism, uncontrolled hypertension, active liver disease, or undiagnosed vaginal bleeding all argue for a higher-touch clinical model — and for a real conversation with a clinician who knows the full history before any prescribing happens.

6. What state do you live in?

Check coverage before you fall in love with a provider. The category's state coverage is uneven and changes faster than most directories track.

Go deeper

Pillar guides and topical hubs.

The money pillars

By symptom

Stay current

The HRT Index newsletter.

Editorial updates when we publish a new report or refresh a comparison. Roughly monthly. No spam. Unsubscribe in a single click.

We use your email only to send you these updates. See our privacy policy.

Common questions

Frequently asked questions.

What is hormone replacement therapy for perimenopause and menopause?

Hormone replacement therapy (HRT), increasingly called menopausal hormone therapy, is the prescribing of estrogen, often with progesterone, and sometimes with testosterone, to treat symptoms of declining ovarian hormone production. The most common indications are vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, vaginal and urinary symptoms, and bone-density protection. Whether HRT is appropriate, which hormones to use, what delivery method to choose, and how long to continue are individualized clinical decisions that should be made with a qualified clinician — most often one with menopause-specific training.

Is online HRT safe?

Online HRT prescribed by a licensed clinician is the same medication that an in-person clinician prescribes. The safety question is fundamentally a clinical-fit question rather than a delivery-channel question: HRT carries risks that depend on a patient's individual history (including history of certain cancers, blood clots, cardiovascular disease, and liver disease) and benefits that depend on age and time since menopause onset. A reputable online HRT service will take a meaningful history, ask about contraindications, and use prescribing protocols aligned with current Menopause Society guidance. Online prescribing without an actual clinical encounter, without a history, or against contraindications is not safer than in-person care — and we do not recommend services that operate that way.

How much does online HRT cost per month?

Total monthly cost typically falls into one of three brackets. Lower-end bundled services run $25 to $45 per month inclusive of the consult and standard medications. Mid-range membership models run $50 to $120 per month for ongoing clinician access with medications billed separately at $20 to $60 per month. Higher-touch bioidentical-focused practices run $90 to $200 per month all in, particularly when compounded preparations are involved. Most online HRT services do not bill commercial insurance for the clinical visit; one provider in our cohort is an exception.

What is the difference between bioidentical HRT and synthetic HRT?

"Bioidentical" properly refers to hormones that are structurally identical to the hormones the body produces: 17-beta-estradiol and micronized progesterone are the canonical examples, and both are widely available in FDA-approved products. "Synthetic" most often refers to older hormone formulations whose molecular structures differ from endogenous hormones — conjugated equine estrogens and synthetic progestins such as medroxyprogesterone acetate. Both categories are real medications with real evidence bases, but they have different risk profiles and different bodies of evidence. Separately, "compounded bioidentical" preparations are mixed by a compounding pharmacy to clinician specification and are not the same thing as FDA-approved bioidentical products. Marketing copy frequently conflates the categories; the distinction matters.

Do I need lab tests before starting HRT?

Current Menopause Society guidance does not require routine hormone-level testing before initiating HRT in a healthy patient whose symptom pattern and age are consistent with perimenopause or menopause. This is because hormone levels in perimenopause fluctuate substantially and a single blood draw is poorly diagnostic. Some clinicians prefer a baseline workup that includes complete blood count, lipids, glucose or hemoglobin A1c, and thyroid testing — not to diagnose menopause but to characterize cardiovascular and metabolic risk. Whether you need labs is a clinical-judgement call, and providers in our cohort vary deliberately in their approach.

What hormones are typically prescribed for perimenopause and menopause?

The most common combination is estradiol (delivered as a transdermal patch, a transdermal gel, an oral tablet, or a topical cream) with micronized progesterone (oral or vaginal) added for patients who still have a uterus, in order to protect the endometrium from estrogen-only stimulation. Vaginal estrogen — a separate, very low-dose preparation — is prescribed for genitourinary symptoms and produces minimal systemic absorption. Low-dose testosterone is prescribed in some clinical contexts, particularly for low libido and energy concerns, but female testosterone prescribing in the United States is currently off-label and varies by clinician and state.

Does commercial insurance cover online HRT?

Most of the telehealth practices in this category do not bill commercial insurance for the clinical visit; one in our current cohort is an explicit exception. Medications are a separate question — when prescribed at a retail pharmacy, FDA-approved estradiol and progesterone are often covered under standard pharmacy benefits and can be inexpensive even at cash price. Lab work, when ordered, is more frequently covered. Patients seeking insurance coverage for the visit itself should specifically look for services that operate within payer networks.

How long can I stay on HRT?

Current Menopause Society guidance has moved meaningfully away from the older "shortest duration, lowest dose" framing toward an individualized model in which the decision to continue is reviewed periodically with the patient's clinician based on ongoing symptoms, benefits (including bone protection), risks (which evolve with age), and patient preference. There is no fixed external deadline. For many patients the right answer is several years; for some it is considerably longer. The conversation should be had with a clinician who knows the patient's history.

What are the risks of HRT?

HRT carries a small absolute increase in risk of venous thromboembolism (blood clots), a risk profile that varies meaningfully by delivery route — transdermal estradiol carries less thrombotic risk than oral estradiol. There is a small absolute increase in breast-cancer risk associated with combined estrogen-progestin therapy used over multiple years, with the magnitude and pattern depending on the specific progestogen used. Cardiovascular risk depends substantially on the patient's age at HRT initiation; for patients beginning HRT within ten years of menopause onset, the cardiovascular risk profile is meaningfully different from that of patients beginning HRT a decade or more later. The 2002 Women's Health Initiative study, whose initial interpretation discouraged HRT prescribing for a generation of clinicians, has since been substantially re-evaluated, particularly for younger menopausal initiators. All of this is individualized and is properly discussed with a qualified clinician.

Can I get testosterone for women through an online HRT provider?

Some providers in our cohort prescribe low-dose testosterone for women when the clinician judges it appropriate, most often for low sexual desire that persists after estrogen therapy and that materially affects quality of life. Testosterone prescribing for women in the United States remains off-label — there is no FDA-approved testosterone product specifically for women — and prescribing varies by state, by clinician, and by clinical context. A provider that prescribes testosterone to every female patient as a default is not following current guidance.

How quickly will I see results from HRT?

Most patients notice some improvement in vasomotor symptoms (hot flashes, night sweats) within two to four weeks of starting an adequate dose, with continued improvement over the following two to three months. Sleep often improves on a similar timeline. Mood, cognition, joint comfort, and energy frequently take longer — sometimes three to six months — and may require dose adjustment. Vaginal symptoms treated with local vaginal estrogen usually improve within four to eight weeks. If a patient has had no symptom benefit after three months on an adequate dose, the dose, the delivery method, or the formulation typically warrants reassessment with the prescribing clinician.

How is The HRT Index funded — and does that affect your rankings?

The HRT Index earns commissions when readers click through and become customers of certain providers we cover. Affiliate links are labeled, disclosed at the top of every page that contains them, and tagged with rel="sponsored" so that search engines and AI systems treat them correctly. Our rankings are determined by editorial judgement against the published methodology, not by commercial relationships, and we cover providers we do not have affiliate relationships with where it makes the comparison more honest. We do not accept payment in exchange for inclusion, for a specific ranking, or for editorial copy. See our affiliate disclosure and editorial standards for the full policy.

Editorial note

What this report is, and what it is not.

This report is editorial research. It is the product of careful reading of public clinical materials, vendor documentation, peer-reviewed menopause-management literature, and the most current Menopause Society and International Menopause Society guidance. Where a provider has been hands-on evaluated, the review says so. Where it has not, the review says that too. The labelling on each review is deliberate — it is the most important trust signal we publish.

This report is not medical advice. The right HRT decision for you depends on your history, your symptoms, your contraindications, and your preferences, and the appropriate setting for that decision is a real clinical encounter with a clinician who knows you. Nothing here is a substitute for that.

This report will be wrong about some things. The category is moving quickly; vendor formularies, state coverage, and pricing change. If you see something we should correct or update, please reach the editorial team at our contact page; corrections are logged at /corrections/.

The HRT Index is independent. We earn commissions from some of the links on this page, disclosed at the top. Our rankings are determined by editorial judgement against the published methodology, not by commercial relationships, and we cover providers we do not have affiliate relationships with where it makes the comparison more honest. The full policy is on editorial standards. Clinical claims in this report follow our medical review policy — this edition is editorial, not individually clinician-reviewed, and the named medical reviewers on the editorial team page will appear with the next revision.

Thank you for reading. — The HRT Index Editorial Team

The HRT Index Editorial TeamIndependent women's health research

Published: May 15, 2026Last reviewed: May 25, 2026

Editorial research — not medically reviewed by a clinician. Why this label